AbbVie Inc (ABBV)vsEvotec SE ADR (EVO)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
EVO
Evotec SE ADR
$3.11
+5.78%
HEALTHCARE · Cap: $1.04B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 7658% more annual revenue ($61.16B vs $788.37M). ABBV leads profitability with a 6.9% profit margin vs -13.1%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
EVO
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for EVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -11.7% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : EVO
The strongest argument for EVO centers on Price/Book. Revenue growth of 14.5% demonstrates continued momentum. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : EVO
The primary concerns for EVO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while EVO is a turnaround play — different risk/reward profiles.
EVO carries more volatility with a beta of 1.24 — expect wider price swings.
EVO is growing revenue faster at 14.5% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 43/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a prominent global biotechnology firm headquartered in Hamburg, Germany, specializing in end-to-end drug discovery and development solutions for the pharmaceutical and biotech industries. The company employs a synergistic approach, collaborating with both established pharmaceutical giants and cutting-edge academic institutions to accelerate the advancement of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline of projects, Evotec is strategically positioned to leverage emerging opportunities in the biopharmaceutical landscape, reinforcing its essential role in driving healthcare innovation and improving patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?